DOVA PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-0.07% | +269.92% |
Financials (USD)
| Sales 2017 | - | Sales 2018 | 10.36 | Capitalization | 214M |
|---|---|---|---|---|---|
| Net income 2017 | -30M | Net income 2018 | -72M | EV / Sales 2017 | - |
| Net cash position 2017 | 64.53M | Net cash position 2018 | 84.34M | EV / Sales 2018 | 12,500,634 x |
| P/E ratio 2017 |
-20.6
x | P/E ratio 2018 |
-2.92
x | Employees | - |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 48.06% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Mahmood Ladha
PSD | President | 60 | 19-11-11 |
Lee F. Allen
CTO | Chief Tech/Sci/R&D Officer | 72 | 17-03-31 |
Marc Banjak
LAW | General Counsel | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Henrik Stenqvist
BRD | Director/Board Member | 57 | 19-11-11 |
Guido Oelkers
BRD | Director/Board Member | 59 | 19-11-11 |
| Director/Board Member | 55 | 19-11-11 |
Dova Pharmaceuticals Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company's initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company's product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| +269.92% | 808M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -2.42% | 21.66B | |
| -18.35% | 20.77B | |
| -8.33% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- DOVA Stock
